Sanofi (NASDAQ:SNY) Shares Purchased by Addison Advisors LLC

Addison Advisors LLC raised its stake in Sanofi (NASDAQ:SNY) by 22.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,311 shares of the company’s stock after buying an additional 237 shares during the quarter. Addison Advisors LLC’s holdings in Sanofi were worth $76,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC lifted its stake in Sanofi by 773.4% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 5,651 shares of the company’s stock worth $275,000 after acquiring an additional 5,004 shares in the last quarter. SG Americas Securities LLC boosted its position in Sanofi by 3.0% in the 1st quarter. SG Americas Securities LLC now owns 15,690 shares of the company’s stock valued at $763,000 after buying an additional 456 shares during the period. Sei Investments Co. raised its stake in shares of Sanofi by 9.3% in the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after acquiring an additional 47,297 shares in the last quarter. QRG Capital Management Inc. grew its stake in Sanofi by 9.7% during the 1st quarter. QRG Capital Management Inc. now owns 134,520 shares of the company’s stock worth $6,538,000 after purchasing an additional 11,902 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in Sanofi by 8,492.4% during the 1st quarter. Russell Investments Group Ltd. now owns 616,506 shares of the company’s stock worth $29,962,000 after purchasing an additional 609,331 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on SNY shares. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Argus increased their target price on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a report on Friday, July 26th. Finally, Citigroup raised Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $50.62 on Tuesday. The stock has a market capitalization of $128.46 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 1.31 and a beta of 0.61. The firm’s fifty day simple moving average is $55.38 and its 200-day simple moving average is $52.24. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65. Sanofi has a 12 month low of $45.13 and a 12 month high of $58.97.

Sanofi (NASDAQ:SNY) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the company earned $2.55 earnings per share. The business’s revenue was up 12.3% compared to the same quarter last year. As a group, equities analysts forecast that Sanofi will post 4.27 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.